Unknown

Dataset Information

0

Zheng W, Wei J, Zebley CC, et al. Regnase-1 suppresses TCF-1+ precursor exhausted T-cell formation to limit CAR-T-cell responses against ALL. Blood. 2021;138(2):122-135.

ABSTRACT:

SUBMITTER:  

PROVIDER: S-EPMC8952182 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Zheng W, Wei J, Zebley CC, et al. Regnase-1 suppresses TCF-1+ precursor exhausted T-cell formation to limit CAR-T-cell responses against ALL. Blood. 2021;138(2):122-135.

Blood 20220301 12

Similar Datasets

Unknown Regnase-1 suppresses TCF-1+ precursor exhausted T-cell formation to limit CAR-T-cell responses against ALL.
| S-EPMC8288655 | biostudies-literature
Unknown Reply to Zheng <i>et al</i>.
| S-EPMC8663016 | biostudies-literature
Transcriptomics CC-122 versus Lenalidomide
2021-06-04 | GSE115328 | GEO
Unknown The role of TCF-1+CD8+ exhausted progenitors and TCF-1 in graft-versus-host responses.
| S-EPMC12507345 | biostudies-literature
Transcriptomics Regnase-1 suppresses TCF-1+ precursor exhausted T cell formation to limit CAR T cell responses against ALL
2021-04-07 | GSE155021 | GEO
Genomics CC-122 versus Lenalidomide
| PRJNA474537 | ENA
Methylation profiling Regnase-1 suppresses TCF-1+ precursor exhausted T cell formation to limit CAR T cell responses against ALL [WGBS]
2021-07-21 | GSE171442 | GEO
Transcriptomics Regnase-1 suppresses TCF-1+ precursor exhausted T cell formation to limit CAR T cell responses against ALL [Microarray Expression]
2021-07-08 | GSE154859 | GEO
Unknown Phase Ib study of combinations of avadomide (CC-122), CC-223, CC-292, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.
| S-EPMC9176062 | biostudies-literature
Unknown CC-122 immunomodulatory effects in refractory patients with diffuse large B-cell lymphoma.
| S-EPMC5325046 | biostudies-literature